“Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity”. SKIN The Journal of Cutaneous Medicine 7, no. 6 (November 13, 2023): s274. Accessed April 18, 2025. https://skin.dermsquared.com/skin/article/view/2385.